List of Tables
Table 1. Macular Degeneration Drug Pipeline Market Trends
Table 2. Macular Degeneration Drug Pipeline Market Drivers & Opportunity
Table 3. Macular Degeneration Drug Pipeline Market Challenges
Table 4. Macular Degeneration Drug Pipeline Market Restraints
Table 5. Global Macular Degeneration Drug Pipeline Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Macular Degeneration Drug Pipeline Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Macular Degeneration Drug Pipeline Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Macular Degeneration Drug Pipeline Product Type
Table 9. Key Companies Time to Begin Mass Production of Macular Degeneration Drug Pipeline
Table 10. Global Macular Degeneration Drug Pipeline Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration Drug Pipeline as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Macular Degeneration Drug Pipeline Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Macular Degeneration Drug Pipeline Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Macular Degeneration Drug Pipeline Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Macular Degeneration Drug Pipeline Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Macular Degeneration Drug Pipeline Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Macular Degeneration Drug Pipeline Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Macular Degeneration Drug Pipeline Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Macular Degeneration Drug Pipeline Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Macular Degeneration Drug Pipeline Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Macular Degeneration Drug Pipeline Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Macular Degeneration Drug Pipeline Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Macular Degeneration Drug Pipeline Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Macular Degeneration Drug Pipeline Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Macular Degeneration Drug Pipeline Sales Value by Region (2019-2024) & (%)
Table 27. Global Macular Degeneration Drug Pipeline Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Macular Degeneration Drug Pipeline Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Macular Degeneration Drug Pipeline Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Macular Degeneration Drug Pipeline Sales Value, (2025-2030) & (US$ Million)
Table 31. Amgen Basic Information List
Table 32. Amgen Description and Business Overview
Table 33. Amgen Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 34. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Amgen (2019-2024)
Table 35. Amgen Recent Developments
Table 36. Roche Basic Information List
Table 37. Roche Description and Business Overview
Table 38. Roche Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 39. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Roche (2019-2024)
Table 40. Roche Recent Developments
Table 41. Adverum Biotechnologies Basic Information List
Table 42. Adverum Biotechnologies Description and Business Overview
Table 43. Adverum Biotechnologies Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 44. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Adverum Biotechnologies (2019-2024)
Table 45. Adverum Biotechnologies Recent Developments
Table 46. AsclepiX Therapeutics Basic Information List
Table 47. AsclepiX Therapeutics Description and Business Overview
Table 48. AsclepiX Therapeutics Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 49. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of AsclepiX Therapeutics (2019-2024)
Table 50. AsclepiX Therapeutics Recent Developments
Table 51. Bioeq AG Basic Information List
Table 52. Bioeq AG Description and Business Overview
Table 53. Bioeq AG Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 54. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Bioeq AG (2019-2024)
Table 55. Bioeq AG Recent Developments
Table 56. Sinocelltech Basic Information List
Table 57. Sinocelltech Description and Business Overview
Table 58. Sinocelltech Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 59. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Sinocelltech (2019-2024)
Table 60. Sinocelltech Recent Developments
Table 61. RemeGen Basic Information List
Table 62. RemeGen Description and Business Overview
Table 63. RemeGen Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 64. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of RemeGen (2019-2024)
Table 65. RemeGen Recent Developments
Table 66. Grifols, S.A. Basic Information List
Table 67. Grifols, S.A. Description and Business Overview
Table 68. Grifols, S.A. Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 69. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Grifols, S.A. (2019-2024)
Table 70. Grifols, S.A. Recent Developments
Table 71. Kyowa Kirin Basic Information List
Table 72. Kyowa Kirin Description and Business Overview
Table 73. Kyowa Kirin Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 74. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Kyowa Kirin (2019-2024)
Table 75. Kyowa Kirin Recent Developments
Table 76. EyePoint Pharmaceutical Basic Information List
Table 77. EyePoint Pharmaceutical Description and Business Overview
Table 78. EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 79. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of EyePoint Pharmaceutical (2019-2024)
Table 80. EyePoint Pharmaceutical Recent Developments
Table 81. IVERIC Bio Basic Information List
Table 82. IVERIC Bio Description and Business Overview
Table 83. IVERIC Bio Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 84. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of IVERIC Bio (2019-2024)
Table 85. IVERIC Bio Recent Developments
Table 86. Kodiak Sciences Basic Information List
Table 87. Kodiak Sciences Description and Business Overview
Table 88. Kodiak Sciences Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 89. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Kodiak Sciences (2019-2024)
Table 90. Kodiak Sciences Recent Developments
Table 91. Ribomic Basic Information List
Table 92. Ribomic Description and Business Overview
Table 93. Ribomic Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 94. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Ribomic (2019-2024)
Table 95. Ribomic Recent Developments
Table 96. Lineage Cell Therapeutics Basic Information List
Table 97. Lineage Cell Therapeutics Description and Business Overview
Table 98. Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 99. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Lineage Cell Therapeutics (2019-2024)
Table 100. Lineage Cell Therapeutics Recent Developments
Table 101. Graybug Vision Basic Information List
Table 102. Graybug Vision Description and Business Overview
Table 103. Graybug Vision Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 104. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Graybug Vision (2019-2024)
Table 105. Graybug Vision Recent Developments
Table 106. CHABiotech Basic Information List
Table 107. CHABiotech Description and Business Overview
Table 108. CHABiotech Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 109. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of CHABiotech (2019-2024)
Table 110. CHABiotech Recent Developments
Table 111. Shanghai Henlius Biotech Basic Information List
Table 112. Shanghai Henlius Biotech Description and Business Overview
Table 113. Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 114. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Shanghai Henlius Biotech (2019-2024)
Table 115. Shanghai Henlius Biotech Recent Developments
Table 116. Bio-Thera Solutions Basic Information List
Table 117. Bio-Thera Solutions Description and Business Overview
Table 118. Bio-Thera Solutions Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 119. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Bio-Thera Solutions (2019-2024)
Table 120. Bio-Thera Solutions Recent Developments
Table 121. Alteogen Basic Information List
Table 122. Alteogen Description and Business Overview
Table 123. Alteogen Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 124. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Alteogen (2019-2024)
Table 125. Alteogen Recent Developments
Table 126. Outlook Therapeutics Basic Information List
Table 127. Outlook Therapeutics Description and Business Overview
Table 128. Outlook Therapeutics Macular Degeneration Drug Pipeline Products, Services and Solutions
Table 129. Revenue (US$ Million) in Macular Degeneration Drug Pipeline Business of Outlook Therapeutics (2019-2024)
Table 130. Outlook Therapeutics Recent Developments
Table 131. Key Raw Materials Lists
Table 132. Raw Materials Key Suppliers Lists
Table 133. Macular Degeneration Drug Pipeline Downstream Customers
Table 134. Macular Degeneration Drug Pipeline Distributors List
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources
Table 138. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Macular Degeneration Drug Pipeline Product Picture
Figure 2. Global Macular Degeneration Drug Pipeline Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Macular Degeneration Drug Pipeline Sales Value (2019-2030) & (US$ Million)
Figure 4. Macular Degeneration Drug Pipeline Report Years Considered
Figure 5. Global Macular Degeneration Drug Pipeline Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Macular Degeneration Drug Pipeline Revenue in 2023
Figure 7. Macular Degeneration Drug Pipeline Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Gene therapy Picture
Figure 9. Small molecules Picture
Figure 10. Stem cell therapy Picture
Figure 11. Gene therapies Picture
Figure 12. Global Macular Degeneration Drug Pipeline Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 13. Global Macular Degeneration Drug Pipeline Sales Value Market Share by Type, 2023 & 2030
Figure 14. Product Picture of Hospital
Figure 15. Product Picture of Research Institute
Figure 16. Product Picture of Commercial
Figure 17. Product Picture of Other
Figure 18. Global Macular Degeneration Drug Pipeline Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Macular Degeneration Drug Pipeline Sales Value Market Share by Application, 2023 & 2030
Figure 20. North America Macular Degeneration Drug Pipeline Sales Value (2019-2030) & (US$ Million)
Figure 21. North America Macular Degeneration Drug Pipeline Sales Value by Country (%), 2023 VS 2030
Figure 22. Europe Macular Degeneration Drug Pipeline Sales Value (2019-2030) & (US$ Million)
Figure 23. Europe Macular Degeneration Drug Pipeline Sales Value by Country (%), 2023 VS 2030
Figure 24. Asia Pacific Macular Degeneration Drug Pipeline Sales Value (2019-2030) & (US$ Million)
Figure 25. Asia Pacific Macular Degeneration Drug Pipeline Sales Value by Country (%), 2023 VS 2030
Figure 26. South America Macular Degeneration Drug Pipeline Sales Value (2019-2030) & (US$ Million)
Figure 27. South America Macular Degeneration Drug Pipeline Sales Value by Country (%), 2023 VS 2030
Figure 28. Middle East & Africa Macular Degeneration Drug Pipeline Sales Value (2019-2030) & (US$ Million)
Figure 29. Middle East & Africa Macular Degeneration Drug Pipeline Sales Value by Country (%), 2023 VS 2030
Figure 30. Key Countries/Regions Macular Degeneration Drug Pipeline Sales Value (%), (2019-2030)
Figure 31. United States Macular Degeneration Drug Pipeline Sales Value, (2019-2030) & (US$ Million)
Figure 32. United States Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
Figure 33. United States Macular Degeneration Drug Pipeline Sales Value by Application (%), 2023 VS 2030
Figure 34. Europe Macular Degeneration Drug Pipeline Sales Value, (2019-2030) & (US$ Million)
Figure 35. Europe Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
Figure 36. Europe Macular Degeneration Drug Pipeline Sales Value by Application (%), 2023 VS 2030
Figure 37. China Macular Degeneration Drug Pipeline Sales Value, (2019-2030) & (US$ Million)
Figure 38. China Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
Figure 39. China Macular Degeneration Drug Pipeline Sales Value by Application (%), 2023 VS 2030
Figure 40. Japan Macular Degeneration Drug Pipeline Sales Value, (2019-2030) & (US$ Million)
Figure 41. Japan Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
Figure 42. Japan Macular Degeneration Drug Pipeline Sales Value by Application (%), 2023 VS 2030
Figure 43. South Korea Macular Degeneration Drug Pipeline Sales Value, (2019-2030) & (US$ Million)
Figure 44. South Korea Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
Figure 45. South Korea Macular Degeneration Drug Pipeline Sales Value by Application (%), 2023 VS 2030
Figure 46. Southeast Asia Macular Degeneration Drug Pipeline Sales Value, (2019-2030) & (US$ Million)
Figure 47. Southeast Asia Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
Figure 48. Southeast Asia Macular Degeneration Drug Pipeline Sales Value by Application (%), 2023 VS 2030
Figure 49. India Macular Degeneration Drug Pipeline Sales Value, (2019-2030) & (US$ Million)
Figure 50. India Macular Degeneration Drug Pipeline Sales Value by Type (%), 2023 VS 2030
Figure 51. India Macular Degeneration Drug Pipeline Sales Value by Application (%), 2023 VS 2030
Figure 52. Macular Degeneration Drug Pipeline Industrial Chain
Figure 53. Macular Degeneration Drug Pipeline Manufacturing Cost Structure
Figure 54. Channels of Distribution (Direct Sales, and Distribution)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation